Melanoma Drugs – new study showing you trends, R&D progress, and predicted revenues
Where is the melanoma drugs market heading? What are the commercial prospects for this market and related technologies? Visiongain’s new report shows you potential revenues and other trends to 2028, discussing data, opportunities and prospects.
Our new 149-page report provides 161 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.
Forecasts from 2018-2028 and other analyses show you commercial prospects
Besides revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces), company profiles and commercial developments.
You find prospects for key submarkets
In addition to analyses of the overall world market, you see revenue forecasts for these four submarkets to 2028:
• Chemotherapeutic melanoma drugs
• Kinase Inhibitors
• Immunotherapeutic melanoma drugs
• Other melanoma drugs
Drugs that can significantly increase disease-free and progression-free survival while also improving patient tolerance will achieve success. Combination therapies aimed at attacking melanoma from multiple angles will prove successful in providing added benefits to patients and manufacturers.
Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find the dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for products
How will leading drugs perform to 2028 at the world level? How will promising products currently in the pipeline perform once they are launched? Our study forecasts sales of 9 melanoma products including these:
• Dabrafenib (Tafinlar)
• Trametinib (Mekinist)
• Vemurafenib (Zelboraf)
• Ipilimumab (Yervoy)
• PegIntron (Sylatron)
• Proleukin (Aldesleukin)
• Pembrolizumab (Keytruda)
• Dacarbzine (DTIC-Dome)
• Temodar/Temodal (Temozolomide)
Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.
What are the prospects for the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 20 national markets to 2028:
• US
• Canada
• Mexico
• Brazil
• Argentina
• Paraguay
• Bolivia
• France
• Germany
• UK
• Spain
• Italy
• Russia
• China
• Japan
• India
• Australia
• Thailand
• Middle East
• Africa
Our analyses show sustained growth, particularly for the markets with high predisposition factors to melanoma such as in Australia, Europe, and the Americas. New product approvals and the development of innovative targeted therapies will influence market growth.
Regulatory, demographic, and commercial developments worldwide will influence the markets both in the established North American and Western European economies, and the fast-rising emerging markets.
Leading companies and potential for market growth
Overall world revenue for melanoma drugs will reach $89bn in 2018, our work forecasts. Rising demand for melanoma drugs, expanding healthcare coverage, recently launched therapies and a strong R&D pipeline will increase sales to 2028.
Our work shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
• Novartis
• Bristol Myers Squibb
• Bayer
• Sanofi
• GSK
• AstraZeneca
• Amgen
• Roche
• Merck & Co.
• Celgene
A company profile gives you the following information:
• Recent financial results
• company’s activities and outlook, including oncology product portfolios and pipelines
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures.
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
Research and development activities
What is happening in the R&D pipeline for melanoma drugs? You see developmental trends, gaining insight into the R&D pipeline for:
• Kinase inhibitors for melanoma
• Immunotherapeutic agents for melanoma
• Vaccines for melanoma
• Genetic therapies for melanoma
• Other therapies for melanoma treatment
What issues will affect the melanoma drugs market?
Our new report discusses issues and events affecting the melanoma drugs market. You will find discussions of many issues and developments, including:
• Reimbursement, regulations, patent expiries, generic competition
• Cost savings and efficiencies
• The use of biologics, targeted and combination therapies
• Understanding melanoma aetiology and progression
• Safety and patient compliance
• Clinical evidence supporting product efficacy
Our investigation gives you multi-level business research and analyses with sales forecasts. You see how that industry and market can perform from 2018 to 2028.
How the Melanoma Drugs Market Forecast 2018-2028 report helps you
In summary our 149-page report gives you the following knowledge:
• Revenue forecasts to 2028 for the overall melanoma drugs market and 4 submarkets – discover the industry’s prospects, finding promising areas for investments and revenues
• Predicted revenues for 9 melanoma drugs – discover prospects for leading products in the market and promising therapies in the pipeline, with forecasted revenues provided to 2028
• Revenue forecast to 2028 for 20 leading national markets – US
Canada, Mexico, Brazil, Argentina, Paraguay, Bolivia, France, Germany, UK, Spain, Italy, Russia, China, Japan, India, Australia, Thailand, Middle East and Africa
• Evaluation of pipeline drugs – find the market potential for leading products currently in the development pipeline in each market segment
• Assessment of 10 leading companies – hear about products, results and strategies, including recent activities and outlook for companies such as Merck, Novartis, GSK, Bristol Myers Squibb, and Roche
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• Opinions from our survey, seeing interviews with industry authorities
You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for melanoma drugs. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Melanoma Drugs Market Overview
1.2 Market Definition
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Market Evaluation & Forecasting Methodology
1.4 Global Melanoma Drugs Market Segmentation
1.5 Overview of Findings
1.6 Why You Should Read This Report
1.7 How This Report Delivers
1.8 Key Questions Answered by This Analytical Report
1.9 Frequently Asked Questions (FAQ)
1.10 Who is This Report For?
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. Introduction to Melanoma Drugs Market
3. Global Melanoma Drugs Market Forecast to 2028
4. Global Melanoma Drugs Market, by Kinase Inhibitors: Market Forecast to 2028
4.1 Overview
4.2 Dabrafenib (Tafinlar)
4.3 Trametinib (Mekinist)
4.4 Vemurafenib (Zelboraf)
4.5 Others
5. Global Melanoma Drugs Market by Immunotherapeutic Agents: Market Forecast to 2028
5.1 Overview
5.2 Yervoy (Ipilimumab)
5.3 Proleukin (Aldesleukin)
5.4 Keytruda (Pembrolizumab)
5.5 PegIntron
5.6 Roferon-A
5.7 Others
6. Global Melanoma Drugs Market by Chemotherapeutic Agents: Market Forecast to 2028
6.1 Overview
6.2 Dacarbazine (DTIC- Dome)
6.3 Temodar/Temodal (Temozolomide)
6.4 Other Chemotherapeutic Agents
7. Regional Melanoma Drugs Market Forecasts to 2028
7.1 Regional Melanoma Drugs Market Forecast Overview
7.2 North American Melanoma Drugs Market Forecast 2018-2028
7.2.1 USA Melanoma Drugs Market Forecast 2018-2028
7.2.2 Canada Melanoma Drugs Market Forecast 2018-2028
7.2.3 Mexico Melanoma Drugs Market Forecast 2018-2028
7.3 South American Melanoma Drugs Market Forecast 2018-2028
7.3.1 Brazil Melanoma Drugs Market Forecast 2018-2028
7.3.2 Argentina Melanoma Drugs Market Forecast 2018-2028
7.3.3 Paraguay Melanoma Drugs Market Forecast 2018-2028
7.3.4 Bolivia Melanoma Drugs Market Forecast 2018-2028
7.3.5 Rest of South America Melanoma Drugs Market Forecast 2018-2028
7.4 European Melanoma Drugs Market Forecast 2018-2028
7.4.1 France Melanoma Drugs Market Forecast 2018-2028
7.4.2 Germany Melanoma Drugs Market Forecast 2018-2028
7.4.3 UK Melanoma Drugs Market Forecast 2018-2028
7.4.4 Spain Melanoma Drugs Market Forecast 2018-2028
7.4.5 Italy Melanoma Drugs Market Forecast 2018-2028
7.4.6 Russia Melanoma Drugs Market Forecast 2018-2028
7.4.7 Rest of Europe Melanoma Drugs Market Forecast 2018-2028
7.5 Asia-Pacific Melanoma Drugs Market Forecast 2018-2028
7.5.1 China Melanoma Drugs Market Forecast 2018-2028
7.5.2 Japan Melanoma Drugs Market Forecast 2018-2028
7.5.3 India Melanoma Drugs Market Forecast 2018-2028
7.5.4 Australia Melanoma Drugs Market Forecast 2018-2028
7.5.5 Thailand Melanoma Drugs Market Forecast 2018-2028
7.5.6 Rest of Asia-Pacific Melanoma Drugs Market Forecast 2018-2028
7.6 Rest of World Melanoma Drugs Market Forecast 2018-2028
7.6.1 Middle East Melanoma Drugs Market Forecast 2018-2028
7.6.2 Africa Cancer Melanoma Drugs Forecast 2018-2028
7.6.3 Other Countries Melanoma Drugs Market Forecast 2018-2028
8. Melanoma Drugs Market, Qualitative Analysis, 2018-2028
8.1 Porter’s Five Forces Analysis of the Melanoma Drugs Market 2018-2028
8.1.1 Bargaining Power of Buyers (Low)
8.1.2 Bargaining Power of Suppliers (Medium)
8.1.3 Threat of New Entrants (Low)
8.1.4 Threat of Substitute Products (Low)
8.1.5 Intensity of Competitive Rivalry (High)
8.2 Drivers, Restraints & Opportunities
8.3 Drivers
8.3.1 Increasing prevalence of melanoma and skin cancer
8.3.2 Favorable regulatory approvals for melanoma drugs
8.3.3 Rise in immunotherapy treatment for melanoma
8.4 Restraints
8.4.1 High costs associated with melanoma treatment
8.4.2 Lack of awareness and slow adoption among of melanoma drugs in emerging markets
8.5 Opportunities
8.5.1 Untapped Potential of Developing Economies
8.5.2 Increase in Support from Private and Government Organizations
9. Leading Companies in Melanoma Drugs Market
9.1 Novartis International AG (Novartis)
9.1.1 Novartis: Company Overview
9.1.2 Novartis: Financial Overview
9.1.3 Novatis: Product Portfolio
9.1.4 Novartis: Recent Developments
9.2 Bristol-Myers Squibb (BMS)
9.2.1 BMS: Company Overview
9.2.2 BMS: Financial Overview
9.2.3 Bristol-Myers Squibb: Product Portfolio
9.2.4 BMS: Recent Developments
9.3 Bayer AG
9.3.1 Bayer AG: Company Overview
9.3.2 Bayer AG: Financial Overview
9.3.3 Bayer AG: Product Portfolio
9.3.4 Bayer AG: Recent Developments
9.4 Sanofi
9.4.1 Sanofi: Company Overview
9.4.2 Sanofi: Financial Overview
9.4.3 Sanofi: Product Portfolio
9.4.4 Sanofi: Recent Developments
9.5 Glaxosmithkline PLC (GSK)
9.5.1 GSK: Company Overview
9.5.2 GSK: Financial Overview
9.5.3 GSK: Product Portfolio
9.5.4 GSK: Recent Developments
9.6 AstraZeneca PLC
9.6.1 AstraZeneca: Company Overview
9.6.2 AstraZeneca: Financial Overview
9.6.3 AstraZeneca: Product Portfolio
9.6.4 AstraZeneca: Recent Developments
9.7 Amgen, Inc. (Amgen)
9.7.1 Amgen: Company Overview
9.7.2 Amgen: Financial Overview
9.7.3 Amgen: Product Portfolio
9.7.4 Amgen: Recent Developments
9.8 F. Hoffmann-La Roche AG
9.8.1 F. Hoffmann-La Roche AG: Company Overview
9.8.2 F. Hoffmann-La Roche AG: Financial Overview
9.8.3 F. Hoffmann-La Roche AG: Product Portfolio
9.8.4 F. Hoffmann-La Roche AG: Recent Developments
9.9 Merck & Co., Inc.
9.9.1 Merck & Co., Inc.: Company Overview
9.9.2 Merck & Co., Inc: Financial Overview
9.9.3 Merck & Co., Inc.: Product Portfolio
9.9.4 Merck & Co., Inc.: Recent Development
9.10 Celgene Corporation (Celgene)
9.10.1 Celgene: Company Overview
9.10.2 Celgene: Financial Overview
9.10.3 Celgene: Product Portfolio
9.10.4 Celgene: Recent Developments
10. Conclusions
10.1 Current Leading Segments
10.2 Leading Regional Markets
10.3 Emerging Markets
10.4 The Future of the Market?
11. Glossary
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
Table of Tables
Table 3.1. Global Melanoma Drugs Market Forecast ($bn, AGR%, CAGR%) 2017-2028
Table 4.1 Melanoma Drugs Market, by Kinase Inhibotors, Forecast ($bn, AGR%, CAGR%) 2017-2028
Table 4.2. Global Dabrafenib Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 4.3. Global Dafrafenib Melanoma Drugs Market Forecast, by Geography, ($bn, AGR%, CAGR%) 2017-2028
Table 4.4. Global Trametinib Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 4.5. Global Trametinib Melanoma Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 4.6. Global Vemurafenib for Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 4.7. Global Vemurafenib for Melanoma Drugs Market, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 4.8. Global Other Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 4.9. Global Other Kinase Inhibitors Melanoma Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.1. Global Melanoma Drugs Market, by Immunotherapeutic Agents($bn, AGR%, CAGR%) 2017-2028
Table 5.2. Global Melanoma Drugs Market Yervoy, ($bn, AGR%, CAGR%) 2017-2028
Table 5.3. Global Melanoma Drugs Market for Yervoy, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.4. Global Melanoma Drugs Market for Proleukin ($bn, AGR%, CAGR%) 2017-2028
Table 5.5. Global Melanoma Drugs Market for Proleukin, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.6. Global Melanoma Drugs Market for Keytruda ($bn, AGR%, CAGR%) 2017-2028
Table 5.7. Global Melanoma Drugs Market for Keytruda, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.8. Global Melanoma Drugs Market for PegIntron Concentrates ($bn, AGR%, CAGR%) 2017-2028
Table 5.9. Global Melanoma Drugs Market for PegIntron by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.10. Melanoma Drugs Market for Roferon-A ($bn, AGR%, CAGR%) 2017-2028
Table 5.11. Global Melanoma Drugs Market for Roferon-A, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.12. Global Melanoma Drugs Market for Other Immunotherapeutic Agents ($bn, AGR%, CAGR%) 2017-2028
Table 5.13. Global Melanoma Drugs Market for Other Immunotherapeutic Agents, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 6.1. Global Melanoma Drugs Market, by Chemotherapeutic Agents($bn, AGR%, CAGR%) 2017-2028
Table 6.2. Global Melanoma Drugs Market for Dacarbazine, ($bn, AGR%, CAGR%) 2017-2028
Table 6.3. Global Melanoma Drugs Market for Dacarbazine, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 6.4. Global Melanoma Drugs Market for TMZ ($bn, AGR%, CAGR%) 2017-2028
Table 6.5. Global Melanoma Drugs Market for TMZ, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 6.6. Global Melanoma Drugs Market for Other Chemotherapeutic Agents ($bn, AGR%, CAGR%) 2017-2028
Table 6.7. Global Melanoma Drugs Market for Other Chemotherapeutic Agents, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 7.1. Global Melanoma Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 7.2. North America Melanoma Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2028
Table 7.3. USA Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.4. Canada Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.5. Mexico Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.6. South America Melanoma Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2028
Table 7.7. Brazil Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.8. Argentina Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.9. Paraguay Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.10. Bolivia Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.11. Rest of South America Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.12. European Melanoma Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2028
Table 7.13. France Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.14. Germany Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.15. UK Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.16. Spain Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.17. Italy Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.18. Russia Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.19. Rest of European Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.20. Asia-Pacific Melanoma Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2028
Table 7.21. China Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.22. Japan Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.23. India Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.24. Australia Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.25. Thailand Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.26 Rest of Asia-Pacific Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.27. Rest of World Melanoma Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2028
Table 7.28. Middle East Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.29. Africa Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.30. Other Countries Melanoma Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 9.1. Novartis: Financial Overview
Table 9.2. Novartis: Financial Overview
Table 9.3. Novartis: Product Portfolio
Table 9.4. Novartis: Recent Developments
Table 9.5. BMS: Company Overview
Table 9.6 BMS: Financial Overview
Table 9.7. BMS: Product Portfolio
Table 9.8. BMS: Recent Developments
Table 9.9. Bayer AG: Company Overview
Table 9.10. Bayer AG: Financial Overview
Table 9.11. Bayer AG: Product Portfolio
Table 9.12. Sanofi: Company Overview
Table 9.13. Sanofi: Financial Overview
Table 9.14. Sanofi: Product Portfolio
Table 9.15. GSK: Company Overview
Table 9.16. GSK: Financial Overview
Table 9.17. GSK: Product Portfolio
Table 9.18. GSK: Recent Development
Table 9.19. AstraZeneca: Company Overview
Table 9.20. AstraZeneca: Financial Overview
Table 9.21. AstraZeneca: Product Portfolio
Table 9.22. AstraZeneca: Recent Development
Table 9.23 Amgen Inc.: Company Overview
Table 9.24. Amgen: Financial Overview
Table 9.25 Amgen Inc.: Product Portfolio
Table 9.26 Amgen Inc.: Recent Developments
Table 9.27. F. Hoffmann-La Roche AG: Company Overview
Table 9.28. F. Hoffmann-La Roche AG: Financial Overview
Table 9.29. F. Hoffmann-La Roche AG: Product Portfolio
Table 9.30. F. Hoffmann-La Roche AG: Recent Developments
Table 9.31. Merck & Co., Inc.: Company Overview
Table 9.32. Merck & Co., Inc.: Financial Overview
Table 9.33. Merck & Co., Inc.: Product Portfolio
Table 9.34. Merck & Co., Inc.: Recent Development
Table 9.35. Celgene: Company Overview
Table 9.36. Celgene: Financial Overview
Table 9.37. Celgene: Product Portfolio
Table of Figures
Figure 1.1. Melanoma Drugs Market Segmentation
Figure 2.1 Top winning Strategies of Market Players in Melanoma Drugs Market, 2014-2017
Figure 3.1 Melanoma Drugs, by Kinase Inhibitors, ($bn), 2017-2028
Figure 3.2 Global Melanoma Drugs Market, by Chemotherapeutic Agents, ($bn), 2017-2028
Figure 3.3 Global Melanoma Drugs Market, by Immunotherapeutic Agents, ($bn), 2017-2028
Figure 4.1. Global Melanoma Drugs Market Forecast, by Kinase Inhibitors ($bn) 2017-2028
Figure 4.2 Melanoma Drugs Market, by Kinase Inhibitors, Market Share (%), 2017
Figure 4.3. Dabrafenib Administration: Objectives
Figure 4.4 Global Dafrafenib Melanoma Drugs Market Forecast, by Geography, ($bn) 2017-2028
Figure 4.5 Global Trametinib Melanoma Drugs Market Forecast, by Geography, ($bn) 2017-2028
Figure 4.6 Global Vemurafenib for Melanoma Drugs Market Forecast, by Geography, ($bn) 2017-2028
Figure 4.7 Global Other Kinase Inhibitors Melanoma Drugs Market Forecast, by Geography, ($bn) 2017-2028
Figure 5.1. Global Melanoma Drugs Market, by Immunotherapeutic Agents, Market Share (%), 2017
Figure 5.2. Global Melanoma Drugs Market for Yervoy Forecast, by Geography($bn) 2017-2028
Figure 5.3. Global Melanoma Drugs Market for Proleukin Forecast, by Geography ($bn) 2017-2028
Figure 5.4. Global Melanoma Drugs Market for Keytruda Forecast, by Geography ($bn) 2017-2028
Figure 5.5. Global Melanoma Drugs Market for PegIntron Forecast, by Geography ($bn) 2017-2028
Figure 5.6. Global Melanoma Drugs Market for Roferon-A Forecast, by Geography ($bn) 2017-2028
Figure 5.7. Global Melanoma Drugs Market for Other Immunotherapeutic Agents Forecast, by Geography ($bn) 2017-2028
Figure 6.1. Global Melanoma Drugs Market, by Immunotherapeutic Agents, Market Share (%), 2017
Figure 6.2. Global Melanoma Drugs Market for Dacarbazine Forecast, by Geography($bn) 2017-2028
Figure 6.3. Global Melanoma Drugs Market for TMZ Forecast, by Geography($bn) 2017-2028
Figure 6.4. Global Melanoma Drugs Market for Other Chemotherapeutic Agents Forecast, by Geography ($bn) 2017-2028
Figure 7.1. Global Melanoma Drugs Market Forecast, by Geography, by Geography ($bn) 2017-2028
Figure 7.2. Global Melanoma Drugs Market Forecast, by Geography, Market Share (%), 2017
Figure 7.3. North America Melanoma Drugs Market Forecast, by Country ($bn) 2017-2028
Figure 7.4. North America Melanoma Drugs Market, by Country, Market Share (%), 2017
Figure 7.5. USA Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.6. Canada Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.7 Mexico Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.8 South America Melanoma Drugs Market Forecast, by Country ($bn) 2017-2028
Figure 7.9. South America Melanoma Drugs Market, by Country, Market Share (%), 2017
Figure 7.10. Brazil Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.11. Argentina Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.12. Paraguay Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.13. Bolivia Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.14. Rest of South America Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.15. Europe Melanoma Drugs Market Forecast, by Country ($bn) 2017-2028
Figure 7.16. Europe Melanoma Drugs Market, by Country, Market Share (%), 2017
Figure 7.17. France Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.18. Germany Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.19. UK Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.20. Spain Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.21. Italy Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.22. Russia Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.23. Rest of Europe Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.24. Asia-Pacific Melanoma Drugs Market Forecast, by Country ($bn) 2017-2028
Figure 7.25. Asia-Pacific Melanoma Drugs Market, Market Share (%), 2017
Figure 7.26. China Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.27. Japan Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.28. India Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.29. Australia Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.30. Thailand Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.31. Rest of Asia-Pacific Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.32. RoW Melanoma Drugs Market Forecast, by Country($bn) 2017-2028
Figure 7.33. Rest of World Melanoma Drugs Market, by Country, Market Share (%), 2017
Figure 7.34. Middle East Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.35. Africa Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 7.36. Other Countries Melanoma Drugs Market Forecast ($bn) 2017-2028
Figure 8.1 Porter’s Five Forces Analysis of the Melanoma Drugs Market
Figure 10.1 World Melanoma Drugs, by Kinase Inhibitors, ($bn), 2017-2028
Figure 10.2 World Melanoma Drugs, by Chemotherapeutic Agents, ($bn), 2017-2028
Figure 10.3 World Melanoma Drugs, by Immunotherapeutic Agents, ($bn), 2017-2028
Figure 10.4. World Melanoma Drugs, by Geography, ($bn), 2017-2028
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
